ZTS

ZTS

USD

Zoetis Inc. Class A Common Stock

$119.830-0.600 (-0.498%)

Echtzeitkurs

Healthcare
Drug Manufacturers - Specialty & Generic
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$120.430

Hoch

$121.310

Tief

$118.520

Volumen

8.35M

Unternehmensfundamentaldaten

Marktkapitalisierung

52.8B

Branche

Drug Manufacturers - Specialty & Generic

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

3.12M

Börse

NYQ

Währung

USD

52-Wochen-Spanne

Tief $117.26Aktuell $119.830Hoch $181.85

Ähnliche Nachrichten

Analyst Upgrades

Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $175

Morgan Stanley analyst Erin Wright maintains Zoetis with a Overweight and lowers the price target from $211 to $175.

Mehr anzeigen
Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $175
Analyst Upgrades

Zoetis Stock Outlook Clouded By Rising Competitive Pressures

Zoetis tops Q3 earnings estimates but trims 2025 sales forecast as companion animal growth slows and competition weighs on its outlook.

Mehr anzeigen
Zoetis Stock Outlook Clouded By Rising Competitive Pressures
BusinessWire

Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career

Mehr anzeigen
Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026
BusinessWire

Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing

Mehr anzeigen
Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
BusinessWire

Zoetis Appoints Stephanie Tilenius to its Board of Directors

Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as

Mehr anzeigen
Zoetis Appoints Stephanie Tilenius to its Board of Directors

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.